246 related articles for article (PubMed ID: 24654922)
1. Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis.
Reni M; Wan Y; Solem C; Whiting S; Ji X; Botteman M
J Med Econ; 2014 May; 17(5):338-46. PubMed ID: 24654922
[TBL] [Abstract][Full Text] [Related]
2. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Pelzer U; Blanc JF; Melisi D; Cubillo A; Von Hoff DD; Wang-Gillam A; Chen LT; Siveke JT; Wan Y; Solem CT; Botteman MF; Yang Y; de Jong FA; Hubner RA
Br J Cancer; 2017 May; 116(10):1247-1253. PubMed ID: 28350787
[TBL] [Abstract][Full Text] [Related]
3. Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.
Cortes J; Pérez-García J; Whiting S; Wan Y; Solem C; Tai MH; Margunato-Debay S; Ko A; Fandi A; Botteman M
Clin Breast Cancer; 2018 Oct; 18(5):e919-e926. PubMed ID: 29703690
[TBL] [Abstract][Full Text] [Related]
4. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
McDermott DF; Shah R; Gupte-Singh K; Sabater J; Luo L; Botteman M; Rao S; Regan MM; Atkins M
Qual Life Res; 2019 Jan; 28(1):109-119. PubMed ID: 30191365
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
[TBL] [Abstract][Full Text] [Related]
6. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.
Young R; Mainwaring P; Clingan P; Parnis FX; Asghari G; Beale P; Aly A; Botteman M; Romano A; Ferrara S; Margunato-Debay S; Harris M
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e325-e331. PubMed ID: 29932294
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Ramanathan RK; Goldstein D; Korn RL; Arena F; Moore M; Siena S; Teixeira L; Tabernero J; Van Laethem JL; Liu H; McGovern D; Lu B; Von Hoff DD
Ann Oncol; 2016 Apr; 27(4):648-53. PubMed ID: 26802153
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.
Feliu J; Jorge Fernández M; Macarulla T; Massuti B; Albero A; González González JF; Quintero-Aldana G; Delgado-Mingorance JI; Fernández Montes A; García Piernavieja C; Valladares-Ayerbes M; López Muñoz AM; Mondéjar Solís R; Vicente P; Casado Gonzalez E; González Cebrián I; López-Vivanco G
Cancer Chemother Pharmacol; 2021 Apr; 87(4):543-553. PubMed ID: 33452559
[TBL] [Abstract][Full Text] [Related]
10. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma.
Nebot-Villacampa MJ; Zafra-Morales R; Alfaro-Olea A; Marín-Gorricho R; Casajús-Navasal A; Uriarte-Pinto M
J Oncol Pharm Pract; 2020 Apr; 26(3):603-611. PubMed ID: 31315550
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.
Mahipal A; Tella SH; Kommalapati A; Goyal G; Soares H; Neuger A; Copolla D; Kim J; Kim R
Invest New Drugs; 2019 Jun; 37(3):473-481. PubMed ID: 30298303
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study.
Xu R; Yu X; Hao J; Wang L; Pan H; Han G; Xu J; Zhang Y; Yang S; Chen J; Ying J; Dai G; Li M; Begic D; Lu B; Shen L
BMC Cancer; 2017 Dec; 17(1):885. PubMed ID: 29273007
[TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
15. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Fernández A; Salgado M; García A; Buxò E; Vera R; Adeva J; Jiménez-Fonseca P; Quintero G; Llorca C; Cañabate M; López LJ; Muñoz A; Ramírez P; González P; López C; Reboredo M; Gallardo E; Sanchez-Cánovas M; Gallego J; Guillén C; Ruiz-Miravet N; Navarro-Pérez V; De la Cámara J; Alés-Díaz I; Pazo-Cid RA; Carmona-Bayonas A
BMC Cancer; 2018 Nov; 18(1):1185. PubMed ID: 30497432
[TBL] [Abstract][Full Text] [Related]
17. [Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use].
Ferris Villanueva E; Martínez Penella M; Cerezuela Fuentes P; Guerrero Bautista R; García Márquez A; Mira Sirvent Mdel C
Farm Hosp; 2015 May; 39(3):181-5. PubMed ID: 26005895
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; Chung JB; An C; Park MS; Jung SY; Bang S
Semin Oncol; 2017 Dec; 44(6):420-427. PubMed ID: 29935903
[TBL] [Abstract][Full Text] [Related]
20. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.
Cascinu S; Berardi R; Bianco R; Bilancia D; Zaniboni A; Ferrari D; Mosconi S; Spallanzani A; Cavanna L; Leo S; Negri F; Beretta GD; Sobrero A; Banzi M; Morabito A; Bittoni A; Marciano R; Ferrara D; Noventa S; Piccirillo MC; Labianca R; Mosconi C; Casadei Gardini A; Gallo C; Perrone F
Eur J Cancer; 2021 May; 148():422-429. PubMed ID: 33812334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
